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Abstract Prostate cancer is one of the most common solid
tumors affecting men. Localized stages can be cured,
however, once disseminated to distant organs the median
survival drops below 12 months. The challenge for the
future consists of unifying gained insights of cellular signal
dysfunctioning (‘‘theragates’’) with the knowledge of dis-
ease detection (‘‘theragnostics’’) in personalized therapy. In
solid malignancies, multiple signal transduction molecules
are often deregulated simultaneously, within the same
tumor. A multi-targeted approach may possibly improve
efficacy, but will also increase toxicity, thus, potentially
limiting the use of various combinations. On the other hand,
well-established treatment modalities in prostate cancer,
such as radiotherapy with its known efficacy and limited
toxicity, may be an attractive combination partner for pro-
tein kinase inhibitors. Deregulation of the epidermal growth
factor receptor (EGFR) signal transduction pathway is
observed in a variety of solid tumors, including prostate
cancer. Furthermore, one important DNA repair mechanism
is dependent on EGFR nuclear translocation, thus, provid-
ing a rationale for combining radiotherapy with EGFR
inhibitors. This article reviews current knowledge regarding
this combination paradigm, revealing an intriguing therapy
option to be explored for patients with advanced prostate
cancer.
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Introduction
Prostate cancer (PCa) represents a paradigm of hormone-
driven malignancy. In patients with localized or locally
advanced disease, the combination of hormonal treatment
with radiotherapy has shown synergistic effects resulting in
improved survival rates [1]. Patients with distant disease
are usually restricted to treatment with systemic therapy
primarily applying androgen manipulation either as
androgen deprivation or androgen blockade, or both.
Despite high response rates initially, all patients with
metastatic disease treated with androgen deprivation will
eventually progress and become clinically refractory to
androgen manipulation (Fig. 1). In these patients, con-
ventional conformal, external beam radiation or surgery are
mainly used in symptomatic patients with focally limited
problems. The aim of this approach is to prevent local
symptoms and to achieve long-lasting local control without
increasing local morbidity. However, in patients with
advanced disease the outcome is dismal.
A multi-targeted approach may possibly improve sur-
vival, but will also increase toxicity. In this situation, well-
studied modalities in PCa, such as radiotherapy with its
known efficacy and limited toxicity, may be an interesting
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combination partner with tyrosine kinase inhibitors (TKIs)
[2]. However, sustained tumor control by radiotherapy is
depending on a variety of issues including tumor hetero-
geneity and intrinsic biological factors like hypoxia, cell
proliferation, apoptosis, angiogenesis and radiation resis-
tant gene expression, resulting in tumor cell survival and
regrowth. The metastatic potential is essentially influenced
by hypoxia, leading to robust circulating cells with
acquired stem cell-like properties characterized by the
epithelial-mesenchymal transition (EMT), being able to
escape androgen manipulation [3].
To further improve the outcome of patients with meta-
static PCa, suitable molecular biomarkers and functional
imaging may be utilized in identification of differently
aggressive areas in a biologically inhomogeneous tumor
mass that can be individually and more appropriately tar-
geted using innovative image guided radiotherapy (IGRT)
and improved intensity modulated radiotherapy, both by
external irradiation (IMRT) and brachytherapy (IMBT).
Thus, a combination of therapy and diagnostics (‘‘therag-
nostics’’) may take morphological and functional proper-
ties of the tumor into account, also utilizing non-invasive
imaging modalities like dynamic contrast-enhanced
magnetic resonance imaging (MRI), diffusion-weighted
MRI and MR spectroscopy in order to acquire valuable
information about metabolic composition, vascularization,
hypoxia and structure (Fig. 2), and translate these into a
personalized targeted therapy (‘‘theragates’’) [4–8].
Recent findings indicate that epidermal growth factor
(EGF) signalling is an important mediator of radiotherapy
resistance and promotion of metastasis. Similar to ‘‘therag-
nostics’’, tumor hypoxia and the impact of EGF pathways for
tumor progression might be studied by phenotypically
characterized detached cells, representing a potential
biomarker that can be used in monitoring therapeutic effi-
cacy. Clinical trials to address these new avenues in multi-
modal therapy of PCa (‘‘theragates’’) should be encouraged.
This article reviews currently available state-of-the-art
knowledge of the EGF family in patients with advanced PCa.
EGFR
EGFR is a receptor tyrosine kinase (RTK) belonging to the
ErbB receptor family that comprises four members (ErbB1/
EGFR/human epidermal growth factor receptor 1 (HER1),
ErbB2/HER2/neu, ErbB3/HER3, and ErbB4/HER4), and is
known to control the behavior of normal epithelial cells and
tumors of epithelial cell origin [9]. This growth factor
receptor system is deregulated in many human tumors,
including PCa [10]. Elevated EGFR expression is for instance
associated with the poor clinical prognosis and resistance to
chemotherapy, hormone therapy, and radiotherapy [11, 12].
Structurally, EGF family receptors present an extracel-
lular ligand binding domain, a transmembrane domain, and
a cytoplasmic domain which harbors the intrinsic tyrosine
kinase (TK) activity. Dimerized, transphosphorylated EGF
receptors activate complex and dynamic signaling cascades
that result in specific gene transcription controlling cell
cycle progression, tissue homeostasis, survival and inva-
sion. In a cancer cell, aberrant EGFR signaling promotes
increased proliferation, invasion, migration, differentiation
and enhanced survival by stimulating anti-apoptotic
pathways [10, 13].
The intracellular tyrosine kinase domain of EGF
receptors is highly conserved. Oppositely, the extracellular
domains of EGF receptors are less conserved, and able to
bind to different ligands. The EGF ligand family includes
Fig. 1 In patients with
localized or locally advanced
PCa the combination of
androgen deprivation therapy
(ADT) with radiotherapy (RT)
has shown synergistic effects.
Despite high response rates
initially, all high-risk patients
treated with ADT will
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over ten different molecules, including EGF, heparin-
binding EGF (HB-EGF), betacellulin (BTC), transforming
growth factor a (TGF-a), epiregulin (EPR), amphiregulin
(AR) and five different neuregulins (NRG-1 to NRG-5)
[13]. The ligands that specifically bind to EGFR are EGF,
TGF-a, AR and the newly identified ligand epigen [14, 15],
while BTC, HB-EGF and EPR bind both to EGFR and
other members of the EGF family. Ligand binding induces
or stabilizes receptor homo- or heterodimerization with
other EGF receptors [13]. Subsequently, tyrosine kinases
are activated, and transphosphorylation of the dimerization
partner occurs. The newly phosphorylated tyrosine residues
act as docking sites for intracellular signaling molecules,
which further induce different downstream signaling
pathways, dependent on the receptor pair combination.
These pathways include the Ras-Raf-mitogen-activated
protein kinase (MAPK) cascade, the phosphoinositide
3-kinase (PI3K)-Akt cascade, the Janus kinase (JAK) and
the signal transducer and activator of transcription (STAT)
cascade, as well as the protein kinase C (PKC) cascade
[13, 16, 17]. Figure 3 illustrates some of the complex
signaling interactions derived from EGF receptors.
Because aberrant activation of EGF receptors has been
associated with uncontrolled cell proliferation and survival,
targeting members of the EGFR family seems to be an
attractive and logical option for cancer therapy. Further,
activation of EGFR signaling has been reported to be
mediated by ionizing radiation. Thus, exposure of EGFR
overexpressing tumor cells to ionizing radiation is expected
to activate survival and proliferation mechanisms pre-
dominantly through PI3K-Akt and Ras-Raf-MAPK sig-
naling pathways, which subsequently inhibits apoptosis
and promotes cell proliferation and repopulation [16, 18,
19]. As a consequence, activation of these two pathways is
thought to be the main causes of radiotherapy resistance of
EGFR overexpressing tumors [16, 18, 20, 21].
HER2, HER3, HER4 and the androgen receptor
HER2 (or ErbB2) is unique within the EGF receptor family
since its extracellular domain is fixed in the active confor-
mation, permanently exposing its dimerization arm, thus,
resembling a ligand activated EGF receptor. These structural
Fig. 2 The combination of therapy and diagnostics (‘‘theragnostics’’)
might involve non-invasive visualization of underlying molecular and
tumorphysiological mechanisms by employing imaging techniques like
morphological T2-weighted magnetic resonance imaging (MRI) (upper
left), diffusion-weighted MRI (upper mid and right) and MR spectros-
copy with metabolite quantification, e.g., the (creatine ? choline)/citrate
ratio (lower panel). These techniques can be used to obtain valuable
information that may be utilized in the development of a personalized
targeted therapy (‘‘theragates’’). (Courtesy of Knut Ha˚kon Hole, MD,
Department of Radiology, The Norwegian Radium Hospital, Oslo
University Hospital, Oslo, Norway)
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observations provide an explanation as to why no ligand for
HER2 has been identified so far, and suggest that HER2
dimerization does not require ligand binding [10]. HER2 is,
therefore, always available and is the preferred heterodimer-
ization partner for other ligand-bound ErbB receptors.
HER3 (ErbB3) lacks essential catalytic residues and is
most likely unable to transphosphorylate its dimerization
partner although an alternative enzymatic mechanism has
recently been postulated [22]. HER3, on the other hand, is
a potent inducer of the PI3K-Akt pathway [23]. It is also of
note that the HER2 (no ligand)/HER3 (no kinase) hetero-
dimers have been reported as the strongest signaling
receptor dimers in reconstituted biological systems [10].
HER4 (ErbB4) is the most recent member in the EGF
receptor family and is much less characterized. HER4 not
only transduces signals the standard way (homo- and/or
heterodimerization), but also acts as a direct transcriptional
regulator when activated by the proteolytic processing
pathway (metallo protease and c-secretase) [24].
The androgen receptor (AR) is a key molecular deter-
minant in the progression of PCa towards the hormone-
refractory state of the disease. Studies have shown that
EGF kinase signals are mandatory for optimal AR func-
tioning at low androgen concentrations and that these sig-
nals are not mediated through EGFR, but rather through the
association of HER2 with other members of the EGF
receptor family. Thus, overexpression of HER2 may
enhance AR function and consequently also promote
androgen resistant growth [25, 26]. Recently, Jain et al.
[27] also demonstrated that EGFR kinase inhibition caused
oncogenic switch to HER2 signaling in a preclinical study.
Thus, the strong involvements of both EGFR and HER2 in
cell signaling pathways make both receptors attractive
targets for therapeutic intervention, separately as mono-
target inhibition, but particularly as dual-targeted therapy.
EGF and radiotherapy
Multiple evidences indicate that elevated EGFR expression
is an important determinant of radiation response and that
EGFR exhibits a radioprotective function [16, 18, 20, 21].
The radiation resistance is mainly thought to occur due to
the activation of signaling cascades leading to tumor cell
Fig. 3 The epidermal growth factor (EGF) receptor family, also
known as the ErbB receptor family, consists of four different
members; EGFR, human epidermal growth factor receptor (HER) 2,
HER3 and HER4. Besides transforming growth factor a (TGF-a), at
least ten additional ligands with various EGF receptor affinities have
been described. Ligand binding has been reported to stabilize the
various combinations of receptor homo- and heterodimers, thereby
promoting close vicinity of the intracellular kinase domains. This
results in receptor transactivation, leading to engagement of down-
stream signaling pathways, which ultimately result in gene transcrip-
tion controlling cell cycle progression, tissue homeostasis, survival
and invasion
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survival, repopulation and proliferation. Recent studies
have identified novel radioprotective mechanisms of
EGFR, where EGFR is shown to be involved in radiation-
induced nuclear translocation of the receptor and interac-
tions with the DNA-dependent protein kinases (DNA-PKs),
being the main components in the non-homologous
end-joining (NHEJ) DNA repair pathway [18].
The radioprotective functions mediated by EGFR can be
separated into three phases as function of time (Fig. 4)
[18]:
1. Early phase of DNA repair (0–4 h) This phase involves
radiation-induced translocation of EGFR and interac-
tions with the DNA repair enzyme, DNA-PK. EGFR is
present in the perinuclear space of unirradiated cells.
After irradiation, ligand-independent translocation of
the EGFR into the nucleoplasm is induced by a process
involving free radicals [28, 29]. Further, nuclear EGFR
binds to the catalytic regulatory subunits of DNA-PK,
DNA-PKcs, and the regulatory subunits Ku70 and Ku80
of DNA-PK. The interaction of EGFR with DNA-PKcs
relates to radiation-induced DNA-PKcs phosphoryla-
tion which controls the disassembly of DNA-PKcs and
the rejoining of DNA double strand breaks (DSBs), thus
leading to cell survival [28].
2. Inhibition of DNA damaged-induced apoptosis phase
(4–24 h) Normally, tumor cells undergo rapid apopto-
tic cell death either prior to cell division or during a
second phase where cells with unrepaired DSBs
emerge from radiation-induced cell cycle arrest.
Oppositely, radiation-induced activation of EGFR has
been shown to confer resistance to apoptosis through
activation of the PI3K and Akt signaling pathway,
thus, cell survival is maintained [30, 31].
3. Proliferation and repopulation phase ([24 h) The
cells emerging from radiation-induced cell cycle arrest
after repair of DNA damage exhibit a proliferation and
repopulation advantage, since the EGFR-dependent
Ras/Raf/MEK/ERK and STAT signaling pathways are
activated, thus, a survival advantage is supported [32].
These findings suggest that it might be possible to sen-
sitize tumors to radiation by blocking the radiation-induced
nuclear import of EGFR by treatment with EGFR (and
HER2) inhibitors. Jooensu et al. [33] recently showed
additive effects combining gefitinib with radiotherapy in
patients with PCa in a phase I/II trial.
Relation to hypoxia
Studies have shown upregulation of EGFR expression
under hypoxic conditions. Thus, hypoxia is expected to be
reduced after treatment with EGFR inhibitors, possibly
leading to an improvement in local tumor control after
irradiation [20, 21]. In addition to the adaptive changes
induced by hypoxia on EGFR, interactions also exist
between EGFR and angiogenesis, as shown by the anti-
angiogenic activity of EGFR inhibitors. In vitro, reduced
expression of vascular endothelial growth factor (VEGF)
has been shown after incubation with gefitinib, an EGFR
tyrosine kinase inhibitor (TKI) [34, 35]. In vivo, reduced
vessel density has been shown after both mAb and EGFR
TKI application, where the effect also was apparent after
combination of the EGFR inhibitor with radiation [35]. In
this respect, the concept of normalization of vasculature,
which has been observed following treatment with anti-
angiogenic therapies, also needs to be considered. Whereas
the vision of anti-angiogenic therapies originally was to
destroy the tumor vasculature in order to reduce oxygen
and nutrient status of the tumors, these therapies may also
transiently lead to a balance between anti-angiogenic and
pro-angiogenic factors and, thus, normalization of the
tumor vasculature, making it more efficient for oxygen and
drug delivery [36]. Thus, such anti-angiogenic therapy may
theoretically both improve and impair tumor oxygenation
Fig. 4 The radioprotective functions mediated by EGFR can be
separated into three phases as function of time. a The early phase of
DNA repair where EGFR is translocated into the nucleus, interacting
with the regulatory DNA-PK subunits DNA-PKcs, Ku70 and Ku80,
controlling the rejoining of DNA double strand breaks (DSBs). b The
phase of inhibition of radiation-induced apoptosis, where activation of
EGFR promotes PI3K and Akt activation, thus, suppressed apoptosis.
c The proliferation and repopulation phase where EGFR activation
causes tumor cells to emerge from radiation-induced cell cycle arrest
and activate the Ras/Raf/MEK/ERK and STAT pathways, promoting
cell survival
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status, and thereby modulate the effects of radiotherapy in
opposite directions [37]. Our recent preclinical study in
androgen sensitive PCa xenografts also revealed that tumor
vascularization and oxygen status are affected by androgen
deprivation treatment strategies, further influencing the
response to subsequent radiotherapy [38]. Thus, the timing
of such therapeutic interventions in relation to tumor
vascularization status is an important aspect that needs to
be considered.
Further, both cetuximab and gefitinib have shown to
downregulate hypoxia-inducible factor alpha (HIF-1a)
[39]. Downregulation of HIF-1a may thus be a positive
marker to EGFR-targeted therapy. EGF is abundantly
found in bone marrow and is triggering signals in osteo-
blast progenitor cells [15]. The homing niche for micro-
metastasis is apparently a hostile environment with low pH,
acidity and predominantly hypoxic conditions. Micromet-
astatic founder cells adapted to such a micromilieu will
have greater chances to survive. This model of oncogenic
addiction was also recently supported by Brandt et al. in a
study describing HER-dependent upregulation of the
unfolded protein response (UPR) as an adaptation mecha-
nism in breast carcinoma [40, 41].
EGF family inhibitors
Because all four EGF receptors most of the time are
simultaneously expressed at the cell surface of tumor cells,
and because homo- as well as heterodimers are formed
upon growth factor activation, dual inhibition targeting
both EGFR and HER2 has attracted significant interest and
research during the last few years. By broadening the scope
of EGF receptor dimer inhibition and by providing a
complete block (both partners) of all cancer relevant EGF
dimers, a combined treatment targeting both EGFR and
HER2 is likely to improve the antitumor activity compared
to inhibition of only one of the receptors.
First generation small molecule EGFR tyrosine kinase
inhibitors (e.g., gefitinib or erlotinib) have shown to be
effective against EGFR overexpressing tumors. Despite ini-
tial responses patients often develop resistance to these
inhibitors, causing relapse of the tumors. Of note, a phase III
trial including inoperable stage III non-small-cell lung cancer
patients showed that patients receiving gefitinib did not
improve survival compared to the placebo group [42]. The
study was closed before it reached its planned sample size,
with the median survival time being 23 months for the
gefitinib-treated patients and 35 months for the placebo group.
Mechanisms of resistance indicate the need for an
inhibitor that is more broadly active against EGF receptor
tyrosine kinases. In vitro, irreversible inhibitors (e.g., EKB-
569, HKI-272, PF299, 804 and BIBW2992) that covalently
bind and irreversibly inhibit the activity of EGFR and/or
HER2 have shown increased efficacy against cell lines
expressing EGFR mutants resistant to gefitinib and erloti-
nib [43–45]. One of these inhibitors, BIBW2992 (afatinib),
is a new irreversible dual specificity EGFR and HER2
inhibitor designed to covalently bind to Cys 773 of EGFR
and Cys 805 of HER2 [46]. This inhibitor has demonstrated
improvements over first-generation EGFR inhibitors in
lung cancer and squamous cell carcinoma models [47–49].
Tolerability and pharmacokinetics of the inhibitor in
patients have recently been investigated in a phase I study
by Eskens et al. [50], and phase II results reporting clinical
activity of the compound have been described [51–53].
The dual EGFR and HER2 inhibitor GW572016
(lapatinib) might currently be the inhibitor with the highest
clinically significant value so far. First, in vitro studies
demonstrated the inhibitor’s growth-inhibitory effects in
EGFR and HER2 overexpressing cell lines [54]. Further,
two large randomized phase III studies investigated the
addition of lapatinib to chemotherapy and one trial looked
into the combined effect of endocrine therapy with lapat-
inib for patients with advanced breast cancer [55–57]. All
studies showed significantly prolonged time to progression
and to the primary endpoint, and on the basis of the
achieved results, lapatinib was approved by the FDA.
Predictive biomarkers
The Prostate Cancer Clinical Trials Working Group 2
(PCCTWG2) recently advised against reporting prostate
specific antigen (PSA) response rates because these are of
little value given the uncertain significance of a defined
degree of decline from baseline. The clinical decision-
making should not be made on PSA measurements alone,
but also be assisted by suitable biomarkers to critically
select and evaluate patients. These predictive biomarkers
may be able to categorize different molecular types of PCa.
Biomarker studies are on their way and may help charac-
terize resistance mechanisms, as has been seen in colon
cancer for KRAS mutations [58]. In PCa, preliminary
studies suggest that circulating tumor cells (CTCs) can be
used for monitoring treatment response. Thus, we propose
that molecular characterization of CTCs will help identi-
fying therapeutical targets.
During recent years the identification of cytokeratin-
positive mononuclear cells in bone marrow (BM) and
peripheral blood (PB) has become feasible using immu-
nocytochemistry. In addition, molecular detection proce-
dures relying on PSA, cytokeratin 19 or prostate-specific
membrane antigen have been used extensively to identify
the residual tumor cells in BM or PB. In principle, the
DNA of disseminated tumor cells (DTCs) or CTCs may
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also be isolated and amplified by the polymerase chain
reaction (PCR), so that very small numbers of tumor cells
can be detected. Over the last years, there has been a rapid
development of technologies for isolating DTCs, employ-
ing enrichment methods for further characterization of
these cells. The enumeration and characterization of CTCs
in PB can be done by different devices using EpCAM
coating as antibody in the CellSearch system [59], micro-
fluid devices (CTC-chip) [60], or MagSweeper [61]. In
addition, the latest techniques generate microvortices to
significantly increase the number of interactions between
CTCs and the antibody-coated chip surface. In a further
RT-PCR step, RNA may be isolated to study tumor-
specific gene locations. In all devices, the CTCs may
subsequently be characterized by immunofluorescence-
conjugated antibodies (Fig. 5).
In 90% of the patients with advanced PCa, the disease
metastasizes to the bone, also including skeleton involve-
ment [62]. The reason for preferential establishment and
growth of disseminated PCa in BM are still unknown.
Although 70% of the patients have detectable DTCs in the
pre-radical prostatectomy, only 10–25% of those with
organ-confined PCa develop recurrence. The prediction of
whether an individual patient will relapse with progressive
disease years later is still difficult. While there have been
numerous attempts to add prognostic power from other
biological features, none has proven repeatedly to be of
higher predictive value than the traditional Gleason score.
However, in patients treated with curative treatment,
detection of DTCs in BM has shown to be a prognostic
marker [63, 64]. Additional therapeutic benefits might be
captured if tumor dynamics from repeated DTC analysis is
performed [60].
We hypothesize that CTCs have phenotypically detect-
able characteristics related to homing. Especially the BM
environment with its hypoxic acidity might be the best
suitable fit for functionally glycolytic disseminated cells.
Clinical evidence also suggests that patients with tumors
that contain more hypoxic areas have higher rates of
metastases [65]. This is a strong link to CTCs, where tumor
hypoxia may be important in selecting and determining the
metastatic ability of CTCs, as well as their progression
once secondary tumor metastases are established. Still, it is
not known if circulating cells function as early metastatic
founders in ectopic sites, as proposed by Klein et al. [66],
or indicate late linear clonal acceleration in tumorigenesis
[67]. Despite these unsolved questions, hypoxia is a potent
candidate for preparing disseminated CTCs to a beneficial
adapted cellular program conferring survival in distant
sites. EGF and other kinases may function as a link
between EMT in PCa and bone and lymph node homing,
by its ability to recruit BM progenitor cells inducing
autophagy and, thus, improving their chance to survive in a
hypoxic glycolytic niche. Similarly, the EGFR and HER2
axis may be important in detached cell survival, rescuing
ATP supply and protecting CTCs from apoptosis [68]. Also
in the state of homing to the bone EGF secreted from DTCs
could stimulate osteoblast progenitors changing the
receptor activator for nuclear factor jB (RANK)/osteo-
protegerin (OPG) ratio. However, during the process of
undetachment, relevant DTCs must undergo EMT and
incorporate stem cell-like features [69]. In the state of
EMT, embryonic markers are overexpressed, such as
Vimentin, N-cadherin and the RANK ligand (RANKL)
protein, promoting PCa progression [70]. Like-wise,
genetic markers related to EMT, as Snail and Twist, are
upregulated in PCa. In this model, the primary tumor will
be highly responsive to EMT-inducing signals and confer
this potential to dissemination. Especially, RANK-bearing
DTCs have been linked to migration and are preferentially
attracted to a RANKL-enhanced environment, as encoun-
tered in the BM [71].
This may imply that these cells have stem cell-like
properties and are capable to settle in hostile acidic BM
conditions in a state of dormancy [41]. When these per-
sisting cells wake up and initiate a micrometastasis, they
appear genotypically more equal to their primary tumor,
independent of the cause of loss of immunosurveillance
[72]. Thus, detecting the disease stage by addressing the
interplay between the soil (bone marrow, lymph nodes and
other organs) and the seeds (primary tumor and isolated
tumor cells) will be mandatory for adequate successful
intervention.
Fig. 5 Isolated tumor cell detected by immunomagnetic target cell
selection from bone marrow aspirate in an advanced PCa patient.
Green is EGFR and red is HER2 (color figure online)
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Conclusions
Realizing the heterogeneity of prostate cancer, one has to
be aware of the different disease risk features and take into
account the life-time risk of relapse and try to reduce
radical overtreatment in those where treatment is unnec-
essary and actively treat those where cure is possible
(‘‘theragnostics’’). Patients with advanced androgen sensi-
tive disease should be encouraged to enter clinical studies.
The design of these protocols should encompass signal
changes in key mediators of growth and progression in
transformed cells as described in this review. Further sci-
entific work on ‘‘theragates’’ should implement character-
ized novel biomarkers and address their interplay with
radiotherapy in a concept of personalized targeted therapy.
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